var data={"title":"Tacrolimus (topical): Drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tacrolimus (topical): Drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390451?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tacrolimus-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tacrolimus (topical): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=tacrolimus-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tacrolimus (topical): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559507\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Although a causal relationship has not been established, rare cases of malignancy (ie, skin cancer and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including tacrolimus ointment. Avoid continuous long-term use of topical calcineurin inhibitors, including tacrolimus ointment, in any age group, and limit application to areas of involvement with atopic dermatitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pediatrics: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Tacrolimus ointment is not indicated for use in children younger than 2 years of age. Only tacrolimus 0.03% ointment is indicated for use in children 2 to 15 years of age.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559514\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Protopic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559515\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Protopic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564725\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Calcineurin Inhibitor;</li>\n      <li>\n        Immunosuppressant Agent;</li>\n      <li>\n        Topical Skin Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564227\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atopic dermatitis (moderate-to-severe):</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> Apply thin layer of 0.03% or 0.1% ointment to affected area twice daily; rub in gently and completely. Discontinue use when symptoms have cleared. If no improvement within 6 weeks, patients should be re-examined to confirm diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance therapy (off-label use): </i>Apply one application (thin layer of 0.03% or 0.1% ointment) to areas usually affected twice daily twice a week (Schneider 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral lichen planus (off-label use): </b>Topical: Apply thin layer of 0.1% ointment to affected area up to 4 times daily; the treatment period in clinical trials ranged from 4 to 6 weeks (Corrocher 2008; Laeijendecker 2006; Radfar 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriasis (off-label use): </b> Topical: Apply thin layer of 0.03% ointment twice daily; the treatment period in clinical trials was 6 weeks (Liao 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pyoderma gangrenosum (off-label use): </b>Topical: Apply thin layer of 0.1% or 0.3% ointment to affected area once daily (Ghislain 2004; Lyon 2001); the treatment period in one clinical trial (0.3% ointment) was up to 10 weeks (Lyon 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitiligo (off-label use): </b>Topical: Apply thin layer of 0.1% ointment to affected area twice daily; may require several months for adequate response; the treatment period in clinical trials ranged from 10 weeks to 18 months (Majid 2010; Radakovic 2009; Taieb 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564226\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tacrolimus-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tacrolimus (topical): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Moderate to severe atopic dermatitis:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 to 15 years: Apply thin layer of 0.03% ointment to affected area twice daily; rub in gently and completely. Discontinue use when symptoms have cleared. If no improvement within 6 weeks, patients should be re-examined to confirm diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Maintenance therapy (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 to 15 years: Apply one application (thin layer of 0.03% ointment) to areas usually affected twice daily twice a week (Schneider 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Patients experiencing flares should resume twice daily treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564228\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50539367\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50539368\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564286\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protopic: 0.03% (30 g, 60 g, 100 g); 0.1% (30 g, 60 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.03% (30 g, 60 g, 100 g); 0.1% (30 g, 60 g, 100 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559530\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559513\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlhxfqCbSVcZt6Lesgs3QpOw==&amp;TOPIC_ID=9921\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564232\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Wash hands before and after application. Use the smallest amount of ointment needed to control the signs and symptoms of atopic dermatitis. Do not use with occlusive dressings. Do not bathe, shower, or swim right after application. Limit sun exposure during the treatment period. Burning at the application site is most common in first few days; improves as atopic dermatitis improves. Limit application to involved areas. Continue as long as signs and symptoms persist; discontinue if resolution occurs; re-evaluate if symptoms persist &gt;6 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132671\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559531\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Moderate to severe atopic dermatitis: </b>Treatment of moderate to severe atopic dermatitis in immunocompetent patients not responsive to conventional therapy or when conventional therapy is not appropriate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856063\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Atopic dermatitis (maintenance therapy); Oral lichen planus; Psoriasis; Pyoderma gangrenosum; Vitiligo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559512\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tacrolimus may be confused with everolimus, pimecrolimus, sirolimus, temsirolimus</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559547\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">As reported in children and adults, unless otherwise noted. Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema (adults 3% to 4%), hypertension (adults 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (adults 19% to 20%), tingling of skin (2% to 8%), hyperesthesia (adults 3% to 7%), insomnia (adults 4%), paresthesia (adults 3%), depression (adults 2%), pain (1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Burning sensation of skin (43% to 58%), pruritus (41% to 46%), erythema (25% to 28%), skin infection (adults 12%), acne vulgaris (adults 4% to 7%), urticaria (adults 3% to 6%), folliculitis (2% to 6%), skin rash (adults 2% to 5%), dermatological disease (children 4%), vesiculobullous dermatitis (children 4%), contact dermatitis (3% to 4%), pustular rash (adults 2% to 4%), contact eczema herpeticum (children 2%), fungal dermatitis (adults 1% to 2%), sunburn (adults 1% to 2%), alopecia (adults 1%), xeroderma (children 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (3% to 5%), dyspepsia (adults 1% to 4%), abdominal pain (children 3%), gastroenteritis (adults 2%), vomiting (adults 1%), nausea (children 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea (adults 4%), urinary tract infection (adults 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Lymphadenopathy (children 3%), malignant lymphoma, malignant neoplasm of skin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (adults 6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Herpes zoster (1% to 5%), varicella zoster infection (1% to 5%), infection (adults 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia (adults 2% to 3%), weakness (adults 2% to 3%), arthralgia (adults 1% to 3%), back pain (adults 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocular: Conjunctivitis (adults 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media (children 12%), otalgia (children 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Flu-like symptoms (23% to 31%), increased cough (children 18%), asthma (adults 6%), rhinitis (children 6%), pharyngitis (adults 4%), sinusitis (adults 2% to 4%), bronchitis (adults 2%), pneumonia (adults 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children 21%), allergic reaction (4% to 12%), alcohol intolerance (adults 3% to 7%), accidental injury (6%), cyst (adults 1% to 3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports (Limited to important or life-threatening): Abnormality in thinking, abscess, acne rosacea, acute renal failure, aggravated tooth caries, anaphylactoid reaction, anemia, anorexia, anxiety, application site edema, arthritis, arthropathy, basal cell carcinoma, benign neoplasm (breast), blepharitis, bone disease, bursitis, candidiasis, cataract, chest pain, chills, colitis, conjunctival edema, constipation, cutaneous candidiasis, cystitis, dehydration, dermal ulcer, diaphoresis, dizziness, dry nose, dysgeusia, dyspnea, ear disease, ecchymoses, edema, epistaxis, eye pain, furunculosis, gastritis, gastrointestinal disease, heart valve disease, hernia, hyperbilirubinemia, hypercholesterolemia, hypertonia, hypothyroidism, impetigo (bullous), laryngitis, leukoderma, malaise, malignant lymphoma, malignant melanoma, migraine, muscle cramps, nail disease, neck pain, neoplasm (benign), oral candidiasis, oral mucosa ulcer, osteoarthritis, osteomyelitis, otitis externa, pulmonary disease, rectal disease, renal insufficiency, seborrhea, seizure, septicemia, skin carcinoma, skin discoloration, skin hypertrophy, skin photosensitivity, squamous cell carcinoma, stomatitis, syncope, tachycardia, tendon disease, unintended pregnancy, vaginitis, vasodilatation, vertigo, visual disturbance, vulvovaginal candidiasis, xerophthalmia, xerostomia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559539\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tacrolimus or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559540\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy:  <b>[US Boxed Warning]: Topical calcineurin inhibitors have been associated with rare cases of malignancy (including skin and lymphoma); therefore, it should be limited to short-term and intermittent treatment using the minimum amount necessary for the control of symptoms and only on involved areas.</b> Avoid use on malignant or premalignant skin conditions (eg cutaneous T-cell lymphoma). Limit sun and ultraviolet light exposure; use appropriate sun protection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Do not apply to areas of active bacterial or viral infection; infections at the treatment site should be cleared prior to therapy. Patients with atopic dermatitis are predisposed to skin infections, and tacrolimus therapy has been associated with risk of developing eczema herpeticum, varicella zoster, and herpes simplex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphadenopathy: May be associated with development of lymphadenopathy; possible infectious causes should be investigated. Discontinue use in patients with unknown cause of lymphadenopathy or acute infectious mononucleosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: Acute renal failure has been observed (rarely) with topical use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Should not be used in immunocompromised patients. Safety and efficacy have not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin diseases with altered absorption: Not recommended for use in patients with skin disease which may increase systemic absorption (eg, Netherton's syndrome).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: <b>[US Boxed Warning] Use in children &lt;2 years of age is not recommended, only the 0.03% ointment should be used in children ages 2-15.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Topical calcineurin agents are considered second-line therapies in the treatment of atopic dermatitis/eczema, and should be limited to use in patients who have failed treatment with other therapies. Safety not established in patients with generalized erythroderma. If atopic dermatitis is not improved in &lt;6 weeks, re-evaluate to confirm diagnosis. Safety of intermittent use for &gt;1 year has not been established, particularly since the effect on immune system development is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564177\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564178\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9921&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Tacrolimus (Topical) may enhance the dermatologic adverse effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Tacrolimus (Topical). Applicable Isavuconazonium considerations are addressed in separate monographs.<b> Exceptions: </b>Isavuconazonium Sulfate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Tacrolimus (Topical).<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Tacrolimus (Topical). Tacrolimus (Topical) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Topical) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Topical).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May increase the serum concentration of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease the metabolism of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. <b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Tacrolimus (Topical).<b> Exceptions: </b>Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the metabolism of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Reuptake Inhibitor/Antagonists: May decrease the metabolism of Tacrolimus (Topical).<b> Exceptions: </b>TraZODone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of Tacrolimus (Topical). Tacrolimus (Topical) may enhance the adverse/toxic effect of Sirolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Tacrolimus (Topical) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559535\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Tacrolimus crosses the human placenta and is measurable in the cord blood, amniotic fluid, and newborn serum following systemic use. Refer to the Tacrolimus (Systemic) monograph for additional information. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559538\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tacrolimus is excreted into breast milk following systemic administration. Refer to the Tacrolimus (Systemic) monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564194\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Suppresses cellular immunity (inhibits T-lymphocyte activation), by binding to an intracellular protein, FKBP-12 and complexes with calcineurin dependent proteins to inhibit calcineurin phosphatase activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564206\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Minimally absorbed; serum concentrations range from undetectable to 20 ng/mL (~2 ng/mL in majority of adult patients studied)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~0.5% </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564288\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Protopic External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.03% (60 g): $612.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (60 g): $612.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Tacrolimus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.03% (60 g): $520.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (60 g): $520.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992812\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cromus (CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Effac (TW);</li>\n      <li>Limus (BD);</li>\n      <li>Mustopic Oint (IN);</li>\n      <li>Protopec (JO);</li>\n      <li>Protopic (AE, AR, AT, BB, BE, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, ID, IE, IL, IT, KR, KW, LT, LU, LV, MT, NL, NO, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN);</li>\n      <li>Protopis (IS);</li>\n      <li>Protopy (AT, BE, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, MT, NL, PL, PT, RU, SE, SK, TR);</li>\n      <li>Protopyk (UA);</li>\n      <li>Remus (BD, LK);</li>\n      <li>Rocimus (LK, PH);</li>\n      <li>Tacrol (BD, PK);</li>\n      <li>Tacroz (LK);</li>\n      <li>Talimus (LK);</li>\n      <li>Talymus (JP);</li>\n      <li>Vitilimus (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corrocher G, Di Lorenzo G, Martinelli N, et al. Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. <i>J Clin Periodontol</i>. 2008;35(3):244-249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/18269664/pubmed\" target=\"_blank\" id=\"18269664\">18269664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Darsow U, Wollenberg A, Simon D, et al, &quot;ETFAD/EADV Eczema Task Force 2009 Position Paper on Diagnosis and Treatment of Atopic Dermatitis,&quot; <i>J Eur Acad Dermatol Venereol</i>, 2010, 24(3):317-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/19732254/pubmed\" target=\"_blank\" id=\"19732254\">19732254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ehst BD and Warshaw EM, &ldquo;Alcohol-Induced Application Site Erythema After Topical Immunomodulator Use and Its Inhibition by Aspirin,&rdquo; <i>Arch Dermatol</i>, 2004, 140(8):1014-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/15313828/pubmed\" target=\"_blank\" id=\"15313828\">15313828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. <i>Br J Dermatol</i>. 2004;150(5):1052-1053.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/15149540/pubmed\" target=\"_blank\" id=\"15149540\">15149540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laeijendecker R, Tank B, Dekker SK, Neumann HA. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. <i>Acta Derm Venereol</i>. 2006;86(3):227-229.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/16710580/pubmed\" target=\"_blank\" id=\"16710580\">16710580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g (-1) ointment and tacrolimus 0.3 mg g (-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. <i>Br J Dermatol</i>. 2007;157(5):1005-1012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/17935517/pubmed\" target=\"_blank\" id=\"17935517\">17935517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lubbe J and Milingou M, &ldquo;Images in Clinical Medicine. Tacrolimus Ointment, Alcohol, and Facial Flushing,&rdquo; <i>N Engl J Med</i>, 2004, 351(26):2740.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/15616208/pubmed\" target=\"_blank\" id=\"15616208\">15616208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. <i>J Dermatolog Treat</i>. 2001;12(1):13-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/12171681/pubmed\" target=\"_blank\" id=\"12171681\">12171681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Majid I. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. <i>Photodermatol Photoimmunol Photomed</i>. 2010;26(5):230-234.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/20831696/pubmed\" target=\"_blank\" id=\"20831696\">20831696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menter A, Korman NJ, Elmets CA, et al, &quot;Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 3. Guidelines of Care for the Management and Treatment of Psoriasis With Topical Therapies,&quot; <i>J Am Acad Dermatol</i>, 2009, 60(4):643-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/19217694/pubmed\" target=\"_blank\" id=\"19217694\">19217694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Protopic (tacrolimus) [prescribing information]. Madison, NJ: LEO Pharma Inc.; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Radakovic S, Breier-Maly J, Konschitzky R, et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. <i>J Eur Acad Dermatol Venereol</i>. 2009;23(8):951-953.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/19496898/pubmed\" target=\"_blank\" id=\"19496898\">19496898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 2008;105(2):187-193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/18230389/pubmed\" target=\"_blank\" id=\"18230389\">18230389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schachner LA, Lamerson C, Sheehan MP, et al, &quot;Tacrolimus Ointment 0.03% is Safe and Effective for the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients: Results From a Randomized, Double-Blind, Vehicle-Controlled Study,&quot; <i>Pediatrics</i>, 2005, 116(3):e334-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/16140675/pubmed\" target=\"_blank\" id=\"16140675\">16140675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23374261\"></a>Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012<b>. </b><i>J Allergy Clin Immunol.</i> 2013;131(2):295-299.e1-27. doi: 10.1016/j.jaci.2012.12.672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/23374261/pubmed\" target=\"_blank\" id=\"23374261\">23374261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taieb A, Alomar A, B&ouml;hm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Vereology (EADV);Union Europe'enne des Me'decins Spe'cialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. <i>Br J Dermatol</i>. 2013;168(1):5-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-topical-drug-information/abstract-text/22860621/pubmed\" target=\"_blank\" id=\"22860621\">22860621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9921 Version 149.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9559507\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9559514\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9559515\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9564725\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9564227\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9564226\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9564228\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50539367\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50539368\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9564286\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9559530\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9559513\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9564232\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132671\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9559531\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25856063\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9559512\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9559547\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9559539\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9559540\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9564177\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9564178\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9559535\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9559538\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9564194\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9564206\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9564288\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992812\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9921|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tacrolimus-topical-patient-drug-information\" class=\"drug drug_patient\">Tacrolimus (topical): Patient drug information \t</a></li><li><a href=\"topic.htm?path=tacrolimus-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">Tacrolimus (topical): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}